Kaken Pharmaceutical Co., Ltd. (KKPCF)

Market Cap	910.46M +0.0%
Revenue (ttm)	542.37M -6.9%
Net Income	63.44M -17.3%
EPS	1.72 -16.5%
Shares Out	n/a
PE Ratio	15.09
Forward PE	n/a
Dividend	1.21 (4.64%)
Ex-Dividend Date	Mar 30, 2027

Volume	200
Open	26.00
Previous Close	28.12
Day's Range	26.00 - 26.00
52-Week Range	23.65 - 28.96
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 9, 2026

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1917
• Employees: 1,114
• Stock Exchange: OTCMKTS
• Ticker Symbol: KKPCF

Financial Performance

In fiscal year 2026, Kaken Pharmaceutical's revenue was 76.87 billion, a decrease of -18.25% compared to the previous year's 94.04 billion. Earnings were 2.14 billion, a decrease of -84.63%.

Financial numbers in JPY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error